Actos Now for Prevention of Diabetes (ACT NOW)

Trial Profile

Actos Now for Prevention of Diabetes (ACT NOW)

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Glucose intolerance; Type 2 diabetes mellitus
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms ACT-NOW
  • Most Recent Events

    • 16 Sep 2016 Results assessing the effect of pioglitazone on Fibroblast Growth Factor-21 (FGF-21), presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
    • 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association (n = 531).
    • 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top